Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: a propensity score matched analysis

Table 4 Severity and ICU management of AKI and outcomes

Variables	DAP (N = 28)	VAN (N = 44)	p
AKI severity and management
AKI stage 2 or 3, or GFR decrease > 50%	7 (25.0)	25 (56.8)	.008
Maximal variation of GFR except RRT (N = 57), %	-6 [−46 to + 13]	−31 [−49 to −8]	.055
RRT initiated during treatment, n (%)	2 (7.1)	13 (29.5)	.022
Proportion of ICU days with RRT^a, %	0 [0–0]	0 [0–13]	.032
Outcomes
Muscular toxicity (CK > 3xUSL), n (%)	4 (14.3)	0
Hypersensitivity manifestation, n (%)	0	1 (2)
Length of ICU stay^a,b (N = 53), days	9 [4–28]	12 [5–25]	.827
Length of in-hospital stay^a,b (N = 41), days	47 [19–62]	39 [23–52]	.543
28-day mortality (N = 71), n (%)	3 (10.7)	11 (25.6)	.124
180-day mortality (N = 69), n (%)	10 (35.7)	22 (53.7)	.142

Quantitative data are expressed as median [interquartile range], except otherwise specified
^aAfter study drug initiation
^bCensored for inpatient mortality
DAP daptomycin, VAN vancomycin, GFR estimate glomerular filtration rate, RRT renal replacement therapy, AKI acute kidney injury, CK creatine kinase, USL upper superior limit, ICU intensive care unit

ISSN: 1471-2334